Alba, Ana Carolina, Gaztañaga, Juan, Foroutan, Farid, Thavendiranathan, Paaladinesh, Merlo, Marco, Alonso-Rodriguez, David, Vallejo-García, Victor, Vidal-Perez, Rafael, Corros-Vicente, Cecilia, Barreiro-Pérez, Manuel, Pazos-López, Pablo, Perez-David, Esther, Dykstra, Steven, Flewitt, Jacqueline, Pérez-Rivera, José Ángel, Vazquez-Caamaño, Maria, Katz, Stuart D, Sinagra, Gianfranco, Køber, Lars, Poole, Jeanne, Ross, Heather, Farkouh, Michael E, White, James A, Alba, Ana Carolina, Gaztañaga, Juan, Foroutan, Farid, Thavendiranathan, Paaladinesh, Merlo, Marco, Alonso-Rodriguez, David, Vallejo-García, Victor, Vidal-Perez, Rafael, Corros-Vicente, Cecilia, Barreiro-Pérez, Manuel, Pazos-López, Pablo, Perez-David, Esther, Dykstra, Steven, Flewitt, Jacqueline, Pérez-Rivera, José Ángel, Vazquez-Caamaño, Maria, Katz, Stuart D, Sinagra, Gianfranco, Køber, Lars, Poole, Jeanne, Ross, Heather, Farkouh, Michael E, and White, James A
BACKGROUND: Dilated cardiomyopathy is associated with increased risk of major cardiovascular events. Late gadolinium enhancement (LGE) cardiac magnetic resonance imaging is a unique tissue-based marker that, in single-center studies, suggests strong prognostic value. We retrospectively studied associations between LGE presence and adverse cardiovascular events in patients with dilated cardiomyopathy in a multicenter setting as part of an emerging global consortium (MINICOR [Multi-Modal International Cardiovascular Outcomes Registry]).METHODS: Consecutive patients with dilated cardiomyopathy referred for cardiac magnetic resonance (2000-2017) at 12 institutions in 4 countries were studied. Using multivariable Cox proportional hazard and semiparametric Fine and Gray models, we evaluated the association between LGE and the composite primary end point of all-cause mortality, heart transplantation, or left ventricular assist device implant and a secondary arrhythmic end point of sudden cardiac death or appropriate implantable cardioverter-defibrillator shock.RESULTS: We studied 1672 patients, mean age 56±14 years (29% female), left ventricular ejection fraction 33±11%, and 25% having New York Heart Association class III to IV; 650 patients (39%) had LGE. During 2.3 years (interquartile range, 1.0-4.3) follow-up, 160 patients experienced the primary end point, and 88 experienced the arrhythmic end point. In multivariable analyses, LGE was associated with 1.5-fold (hazard ratio, 1.45 [95% CI, 1.03-2.04]) risk of the primary end point and 1.8-fold (hazard ratio, 1.82 [95% CI, 1.20-3.06]) risk of the arrhythmic end point. Primary end point risk was increased in patients with multiple LGE patterns, although arrhythmic risk was higher among patients receiving primary prevention implantable cardioverter-defibrillator and widening QRS.CONCLUSIONS: In this large multinational study of patients with dilated cardiomyopathy, the presence of LGE showed strong